CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Al Sandrock

President and Chief Executive Officer, Voyager Therapeutics

Search every verified Al Sandrock interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Al Sandrock, President and CEO of Voyager Therapeutics, participated in a panel discussion at the USAIC Panel 2026 titled "Turning Breakthroughs into Impact: Unlocking the Rare & Neuro Opportunity" on October 13, 2026. During the session, he discussed the potential of rare disease therapies to offer targeted treatments within viable business models, citing long-standing enzyme replacement therapies for conditions like Gaucher and Fabry disease as examples of sustained commercial success. He also addressed the importance of the blood-brain barrier, referencing the recent approval of a receptor-mediated transport drug for Hunter syndrome as a significant development in delivering therapies to the central nervous system. In the panel's discussion on future research directions, Sandrock expressed agreement that neuroinflammation may be a key area to tackle after tau-targeting approaches, and he suggested that TREM2 remains a promising target despite recent clinical trial results, noting the potential of microglial cells to adopt neuroprotective roles. He also commented on the field's progress in developing new modalities and tools, while observing that neurology has not yet fully realized its anticipated growth compared to oncology, citing conservatism among neurologists and regulatory lag as contributing factors.

Recent appearances

  • USAIC Panel 2026 Turning Breakthroughs into Impact Unlocking the Rare & Neuro Opportunity

    October 13, 2026 · 📺 USAIC

    Panel: Turning Breakthroughs into Impact: Unlocking the Rare & Neuro Opportunity Panelists: Dr. Al Sandrock, President & CEO, Voyager Therapeutics Dr. David Meeker, Chairman & CEO, Rhythm Pharmaceuticals Dr. Ivana Magovcevic-Liebisch, President & CEO, Draig Therapeutics Dr. Priya Singhal, Executive Vice President & Head of Development, Biogen Dr. Steven Paul, Founder and Chair of the Board, Seaport Therapeutics Moderator: Dr. Zandy Forbes, President & CEO, MeiraGTx

    Watch on YouTube ↗

  • Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.

    June 28, 2026 · 📺 Life Science Connect

    On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role of emerging tools like fluid biomarkers in diagnosis and prevention, and why small biotechs take bigger risks than big pharma. Access this and hundreds of ep…

    Watch on YouTube ↗

  • Ep. 335 - Neurology's Coming Inflection Point

    November 20, 2025 · 📺 BioCentury Video

    Voyager CEO and former head of R&D at Biogen Al Sandrock is more optimistic than ever about the prospect of bringing clinically meaningful solutions to patients with Alzheimer’s disease and other neurodegenerative disorders. The threads of progress are finally coming together, he said in a special episode of the BioCentury This Week podcast. From the first disease-modifying therapies for Alzheimer’s disease, to a growing biomarker toolkit, to an expanding set of genetically validated targets in other neurodegenerative conditions — and, crucially, to delivery vehicles capable of broadly and dee…

    Watch on YouTube ↗

  • Alfred Sandrock, MD, PhD: Progressing Parkinson's Therapies and What They Target

    April 24, 2018 · 📺 HCPLive

    The executive vice president and chief medical officer of Biogen explained how crucial it is for potential DMTs to attacki the alpha-synuclein protein.

    Watch on YouTube ↗

  • 2017 WNIF | 1:1 Fireside - Alfred Sandrock

    April 04, 2017 · 📺 World Medical Innovation Forum

    Moderator: Rudolph Tanzi, PhD, Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School Alfred Sandrock, MD, PhD, EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →